Rob May

Rob has managed the design, development and operations of manufacturing for biologics, vaccines, and gene therapies making medicines that have changed the lives of millions of patients. He most recently led the design, build, and operations of a state-of-the-art 170,000-square-foot GMP-grade gene therapy manufacturing plant for clinical and commercial supply at AveXis, where he was Vice President, North Carolina Site Head. Before AveXis, Rob was the U.S. Head of Technical Development Operations for Novartis/GSK Vaccines, where he was responsible for the delivery of several viral vaccine development programs using a variety of production platforms. He also spent 17 years on the biologics manufacturing team at Amgen. Rob received his B.A. in Biology from the University of California, Berkeley.